When we sorted all 22,277 probes present in the U133A gene chip according to their potential to predict relapse in a panel of 724 ERα-positive breast cancer patients treated with ET, SQLE (probe set 209218_at) ranked 1st (hazard ratio=2.67) (Fig. 7e; Supplementary Data 5). Here, ESR1 is linked to breast carcinoma.